Developments in lung SABR
The use of stereotactic ablative radiotherapy (SABR) has expanded in the UK over the past decade. In 2008, the UK SABR Consortium was established to help achieve a consensus in implementing and developing SABR in a safe and managed way. In 2011, the National Radiotherapy Implementation Group (NRIG) report recommended that SABR had become standard of care for the management of medically inoperable early stage non-small cell lung cancer patients (ES-NSCLC).
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.